India, June 30 -- Biocon Biologics Ltd. (BBL), a leading global biosimilars company, announced that its Malaysian subsidiary, Biocon Sdn. Bhd., has surpassed the milestone of supplying over 100 million cartridges of recombinant human insulin (rh-insulin) to Malaysia's Ministry of Health (MoH). This accomplishment highlights the company's ongoing commitment to enhancing diabetes care and ensuring affordable insulin access throughout the country.
Since entering the Malaysian market in 2016, Biocon Biologics has played a key role in transforming diabetes management. The company has delivered over 100 million rh-insulin cartridges, serving more than 345,000 patients. Its public-private partnership with the Malaysian government showcases a succ...